MA27988A1 - Anticorps modifiés contre le IGF-1R humain - Google Patents

Anticorps modifiés contre le IGF-1R humain

Info

Publication number
MA27988A1
MA27988A1 MA28790A MA28790A MA27988A1 MA 27988 A1 MA27988 A1 MA 27988A1 MA 28790 A MA28790 A MA 28790A MA 28790 A MA28790 A MA 28790A MA 27988 A1 MA27988 A1 MA 27988A1
Authority
MA
Morocco
Prior art keywords
human igf
against human
antibody modified
igf
modified against
Prior art date
Application number
MA28790A
Other languages
English (en)
Inventor
Bruce David Cohen
Vahe Bedian
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of MA27988A1 publication Critical patent/MA27988A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticorps modifiés contre le IGF-1R humain La présente invention concerne des anticorps humains, par exemple ceux dirigés contre le récepteur de IGF-1 humain (IGF-1R) qui sont destinés au traitement du cancer, qui possèdent un ou plusieurs résidus mutés choisis remplacés par des résidus de lignée germinale. Un résidu remplacé peut être une mutation somatique dans une région de squelette structural.
MA28790A 2003-08-13 2006-02-13 Anticorps modifiés contre le IGF-1R humain MA27988A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US49520003P 2003-08-13 2003-08-13

Publications (1)

Publication Number Publication Date
MA27988A1 true MA27988A1 (fr) 2006-07-03

Family

ID=34193291

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28790A MA27988A1 (fr) 2003-08-13 2006-02-13 Anticorps modifiés contre le IGF-1R humain

Country Status (37)

Country Link
US (2) US7371378B2 (fr)
EP (1) EP1656391B1 (fr)
JP (1) JP4638870B2 (fr)
KR (1) KR100825156B1 (fr)
CN (1) CN1835975B (fr)
AP (1) AP2006003510A0 (fr)
AR (1) AR045247A1 (fr)
AT (1) ATE484525T1 (fr)
AU (1) AU2004265152A1 (fr)
BR (1) BRPI0413466A (fr)
CA (1) CA2535071A1 (fr)
CL (1) CL2004002035A1 (fr)
CR (1) CR8233A (fr)
DE (1) DE602004029581D1 (fr)
DK (1) DK1656391T3 (fr)
EA (1) EA200600234A1 (fr)
EC (1) ECSP066359A (fr)
ES (1) ES2351395T3 (fr)
GT (1) GT200400158A (fr)
IL (1) IL173273A (fr)
IS (1) IS8266A (fr)
MA (1) MA27988A1 (fr)
MX (1) MXPA06001634A (fr)
NL (1) NL1026829C2 (fr)
NO (1) NO20060542L (fr)
OA (1) OA13234A (fr)
PA (1) PA8608801A1 (fr)
PE (1) PE20050339A1 (fr)
PL (1) PL1656391T3 (fr)
PT (1) PT1656391E (fr)
RS (1) RS20060099A (fr)
TN (1) TNSN06050A1 (fr)
TW (1) TWI294915B (fr)
UA (1) UA85058C2 (fr)
UY (1) UY28464A1 (fr)
WO (1) WO2005016967A2 (fr)
ZA (1) ZA200601231B (fr)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
EP1506286B1 (fr) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Anticorps anti-igfr humain neutralisant
CA2524305C (fr) * 2003-05-01 2015-12-08 Imclone Systems Incorporated Anticorps entierement humains diriges contre le recepteur du facteur de croissance 1 de type insuline
DE602004029581D1 (de) * 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
TW200526684A (en) 2003-11-21 2005-08-16 Schering Corp Anti-IGFR1 antibody therapeutic combinations
KR20080019733A (ko) 2004-07-16 2008-03-04 화이자 프로덕츠 인코포레이티드 항-아이지에프-1알 항체를 사용하는 비-혈액학적악성종양에 대한 조합 치료
FR2873699B1 (fr) * 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
PT1828249E (pt) 2004-12-03 2011-02-25 Schering Corp Biomarcadores para a pré-selecção de pacientes para terapêutica anti-igf1r
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
GB0500417D0 (en) * 2005-01-10 2005-02-16 Cambridge Antibody Tech Method of mutagenesis
JP4875064B2 (ja) * 2005-04-15 2012-02-15 シェーリング コーポレイション 癌を処置または予防するための方法および組成物
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
CA2612449A1 (fr) * 2005-06-17 2006-12-28 Imclone Systems Incorporated Antagonistes de recepteur pour le traitement de cancer osseux metastatique
FR2888850B1 (fr) * 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
AP2008004569A0 (en) * 2006-02-03 2008-08-31 Imclone Systems Inc IGR-IR antagonists as adjuvants for treatment of prostrate cancer
JP2009531371A (ja) * 2006-03-28 2009-09-03 エフ．ホフマン−ラ ロシュ アーゲー 抗ｉｇｆ−１ｒヒト・モノクローナル抗体製剤
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
NZ573187A (en) * 2006-06-02 2011-11-25 Pfizer Prod Inc Circulating tumor cell assay for predicting efficacy of 1gf-1r antagonist therapy
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) * 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2012203443B2 (en) * 2007-03-02 2014-03-06 Amgen Inc. Methods and compositions for treating tumor diseases
AU2008223541B2 (en) * 2007-03-02 2012-04-05 Amgen Inc. Methods and compositions for treating tumor diseases
EP2136839A4 (fr) * 2007-03-22 2010-04-07 Imclone Llc Formulations d'anticorps stables
EP2559771A3 (fr) 2007-05-17 2013-06-12 Bristol-Myers Squibb Company Bio-marqueurs et méthodes pour déterminer la sensibilité aux modulateurs du recepteur du facteur de croissance de l'insuline (IGF1R).
ES2388017T3 (es) 2007-12-21 2012-10-05 Roche Glycart Ag Ensayo de estabilidad de anticuerpos
US20110104256A1 (en) * 2008-03-25 2011-05-05 Yaolin Wang Methods for treating or preventing colorectal cancer
US20110129456A1 (en) * 2008-05-05 2011-06-02 Yaolin Wang Sequential Administration of Chemotherapeutic Agents for Treatment of Cancer
EP2356154A4 (fr) * 2008-11-06 2012-12-19 Alexion Pharma Inc Mise au point d anticorps à immunogénicité réduite et méthodes de fabrication associées
WO2010099139A2 (fr) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Thérapie anti-cancer combinée
EP2236139A1 (fr) 2009-03-31 2010-10-06 F. Hoffmann-La Roche AG Thérapie combinée d'erlotinibe avec un anticorps anti-IGF-1R, qui n'inhibe pas la liaison d'insuline dans le récepteur d'insuline
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
SI2493922T1 (sl) 2009-10-26 2017-06-30 F. Hoffmann-La Roche Ag Postopek za proizvodnjo glikoziliranega imunoglobulina
EP2494070A2 (fr) 2009-10-30 2012-09-05 Bristol-Myers Squibb Company Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r
AU2014262201B2 (en) * 2009-12-23 2016-09-15 Novartis Ag Method for decreasing immunogenicity
KR101721187B1 (ko) * 2009-12-23 2017-03-29 에스바테크 - 어 노바티스 컴파니 엘엘씨 면역원성의 감소 방법
WO2011101328A2 (fr) 2010-02-18 2011-08-25 Roche Glycart Ag Traitement au moyen d'un anticorps anti-egfr de la classe igg humanisé et d'un anticorps contre le récepteur du facteur de croissance 1 analogue à l'insuline
WO2011161119A1 (fr) 2010-06-22 2011-12-29 F. Hoffmann-La Roche Ag Anticorps contre le récepteur du facteur de croissance insulinique i et ses utilisations
RU2012157167A (ru) 2010-07-12 2014-08-20 КовЭкс Текнолоджиз Айэлэнд Лимитед Полифункциональные антительные конъюгаты
MX2013008833A (es) 2011-02-02 2013-12-06 Amgen Inc Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
DK2699598T3 (en) 2011-04-19 2019-04-23 Pfizer COMBINATIONS OF ANTI-4-1BB ANTIBODIES AND ADCC-INducing ANTIBODIES FOR TREATMENT OF CANCER
EP2766497A1 (fr) 2011-10-13 2014-08-20 Bristol-Myers Squibb Company Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir
EP3447071A1 (fr) * 2012-01-09 2019-02-27 Pfizer Healthcare Ireland Anticorps mutants et leur conjugaison
EP2631653A1 (fr) 2012-02-24 2013-08-28 Charité - Universitätsmedizin Berlin Identification de modulateurs de liaison des propriétés d'anticorps réactifs avec un élément de la famille des récepteurs de l'insuline
WO2013152252A1 (fr) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Polythérapie antinéoplasique
BR112015010240A2 (pt) * 2012-11-06 2017-08-22 Medimmune Ltd Terapias de combinação através do uso de mo-léculas de ligação de psl e de pcrv anti-pseudomonas
WO2014177459A2 (fr) 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Anticorps asymétriques modifiés liant à la récepteur fc et procédés d'utilisation
UA118029C2 (uk) 2013-04-29 2018-11-12 Ф. Хоффманн-Ля Рош Аг Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
CN103319598B (zh) * 2013-05-13 2014-10-22 杭州德同生物技术有限公司 抗胰岛素样生长因子-1受体抗体及其编码基因和应用
MX380658B (es) 2014-01-15 2025-03-11 Hoffmann La Roche Variantes de region fc con union mejorada de la proteina a.
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
IL272227B2 (en) * 2017-07-27 2025-09-01 iTeos Belgium SA Anti-tigit antibodies
EP3725806A4 (fr) 2017-12-14 2022-03-30 ABL Bio Inc. Anticorps bispécifique contre a-syn/igf1r et utilisation associée

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6054561A (en) * 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1996033735A1 (fr) 1995-04-27 1996-10-31 Abgenix, Inc. Anticorps humains derives d'une xenosouris immunisee
US6657103B1 (en) * 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
ES2153031T4 (es) 1995-04-20 2001-05-16 Pfizer Derivados del acido arilsulfonil hidroxamico como inhibidores de mmp y tnf.
IL118626A0 (en) * 1996-06-11 1996-10-16 Xtl Biopharmaceuticals Limited Anti HBV antibody
KR20000067904A (ko) 1996-07-18 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 매트릭스 메탈로프로테아제의 포스피네이트계 억제제
KR20000068248A (ko) 1996-08-23 2000-11-25 디. 제이. 우드, 스피겔 알렌 제이 아릴설포닐아미노 하이드록삼산 유도체
KR20010071271A (ko) 1998-05-15 2001-07-28 존 비. 랜디스 방사선 및 성장 인자 수용체 티로신 키나아제 억제제에의한 사람 종양의 치료법
US6682736B1 (en) * 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
HUP0200575A3 (en) 1999-03-25 2004-11-29 Abbott Gmbh & Co Kg Human antibodies that bind human il-12 and methods for producing
ES1042735Y (es) 1999-04-07 2000-02-16 Martinez Fernando Martinez Vehiculo tripersonal de accionamiento a pedales.
US20030165502A1 (en) 2000-06-13 2003-09-04 City Of Hope Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth
DE10033869C2 (de) 2000-07-12 2003-07-31 Karlsruhe Forschzent HTS-Kryomagnet und Aufmagnetisierungsverfahren
ME00502B (me) * 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US7132511B2 (en) 2001-02-19 2006-11-07 Merck Patent Gmbh Modified anti-EGFR antibodies with reduced immunogenicity
SI1461359T1 (sl) 2002-01-18 2007-06-30 Pf Medicament Nova anti IGF-IR protitelesa in njihova uporaba
AU2003231554A1 (en) 2002-04-30 2003-11-17 Kyowa Hakko Kogyo Co., Ltd. Antibody to human insulin-like growth factor
EP1506286B1 (fr) 2002-05-24 2014-03-19 Merck Sharp & Dohme Corp. Anticorps anti-igfr humain neutralisant
GB0212303D0 (en) 2002-05-28 2002-07-10 Isis Innovation Molecular targetting of IGF-1 receptor
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
PL378812A1 (pl) 2003-02-13 2006-05-29 Pfizer Products Inc. Zastosowania przeciwciał przeciw receptorowi insulinopodobnego czynnika wzrostowego I
JP2007528201A (ja) 2003-03-14 2007-10-11 ファルマシア・コーポレーション 癌治療のためのｉｇｆ−ｉ受容体に対する抗体
ES2383014T3 (es) 2003-04-02 2012-06-15 F. Hoffmann-La Roche Ag Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos
DE602004029581D1 (de) * 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper

Also Published As

Publication number Publication date
KR20060035796A (ko) 2006-04-26
DE602004029581D1 (de) 2010-11-25
US20050069539A1 (en) 2005-03-31
US7371378B2 (en) 2008-05-13
ZA200601231B (en) 2007-05-30
CN1835975B (zh) 2012-11-21
MXPA06001634A (es) 2006-04-28
ES2351395T3 (es) 2011-02-04
IL173273A0 (en) 2006-06-11
TW200516145A (en) 2005-05-16
GT200400158A (es) 2005-07-22
TWI294915B (en) 2008-03-21
US20080181891A1 (en) 2008-07-31
JP2007527705A (ja) 2007-10-04
PA8608801A1 (es) 2005-03-03
UA85058C2 (ru) 2008-12-25
CN1835975A (zh) 2006-09-20
CA2535071A1 (fr) 2005-02-24
JP4638870B2 (ja) 2011-02-23
ECSP066359A (es) 2006-10-31
PE20050339A1 (es) 2005-05-17
IL173273A (en) 2011-10-31
AR045247A1 (es) 2005-10-19
IS8266A (is) 2006-01-26
KR100825156B1 (ko) 2008-04-24
EA200600234A1 (ru) 2006-08-25
BRPI0413466A (pt) 2006-10-17
NL1026829C2 (nl) 2005-07-05
UY28464A1 (es) 2005-03-31
CR8233A (es) 2007-01-18
DK1656391T3 (da) 2011-01-03
EP1656391A2 (fr) 2006-05-17
CL2004002035A1 (es) 2005-06-03
PT1656391E (pt) 2010-12-06
PL1656391T3 (pl) 2011-03-31
WO2005016967A2 (fr) 2005-02-24
EP1656391B1 (fr) 2010-10-13
AP2006003510A0 (en) 2006-02-28
WO2005016967A3 (fr) 2005-04-14
TNSN06050A1 (fr) 2007-10-03
OA13234A (en) 2006-12-13
ATE484525T1 (de) 2010-10-15
AU2004265152A1 (en) 2005-02-24
NL1026829A1 (nl) 2005-02-15
US7575746B2 (en) 2009-08-18
NO20060542L (no) 2006-05-03
RS20060099A (sr) 2008-08-07

Similar Documents

Publication Publication Date Title
MA27988A1 (fr) Anticorps modifiés contre le IGF-1R humain
FR22C1052I1 (fr) Anticorps anti-cd19 humanises et leur utilisation dans le traitement des tumeurs, de la transplantation et des maladies auto-immunes
Bowles et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
EP2275134A3 (fr) Utilisation d'anticorps optimisés en ADCC pour traiter les patients faibles répondeurs
MA33387B1 (fr) Polypeptides et procede de traitement
MA39313A1 (fr) Anticorps anti-egfrviii et leurs utilisations dans le traitement de divers cancers
ATE477276T1 (de) Internalisierung von anti cd74 monoklonalen antikörpern und deren verwendungen
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
MA35174B1 (fr) Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines
MA43435B1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre diverses tumeurs (seq id 25 - mrax5-003)
MA45309B1 (fr) Lymphocytes t transfectés et récepteurs de lymphocytes t destinés à être utilisés en immunothérapie contre des cancers
MX2018005512A (es) Agentes de union de esclerostina.
PE20061115A1 (es) Anticuerpos anti-il-12, epitopos, composiciones, metodos y usos
TW200738748A (en) Human monoclonal antibody human CD134 (OX40) and methods of making and using same
WO2007042573A3 (fr) Compositions et procedes pour traiter des troubles de proliferation
EP1893196A4 (fr) Composes diarylhydantoines
CY1114019T1 (el) Μεταλλακτες του αντισωματος anti-cd40
MA30891B1 (fr) Nouveaux anticorps anti-proliferation
EP2100903A3 (fr) Anticorps anti-idiotypiques neutralisant l'activité inhibitrice d'un anticorps inhibiteur dirigé contre le domaine C1 du facteur VIII
MA39821B1 (fr) Molécules de liaison spécifiques de l'il-21 et leurs utilisations
MA45801A1 (fr) Protéines de liaison à l'antigène qui sont des antagonistes du récepteur de leptine
EP1828404A4 (fr) Dispositifs et procédés permettant de déterminer l'activité d'une protéase
DK1711531T3 (da) Neutraliserende anti-TLR4/-MD-2-antistoffer og fremgangsmåder til anvendelse deraf
UA94211C2 (ru) Выделенное полностью человеческое моноклональное cd3 антитело
MA33668B1 (fr) Anticorps chimériques spécifiques pour cd151 et leur utilisation dans le traitement du cancer